骨癌藥物市場：依藥物類型、適應症、通路和地區分類

Bone Cancer Drugs Market, By Drug Type, By Disease Indication, By Distribution Channel, and By Region

出版日期: 2025年08月20日 | 出版商:

Coherent Market Insights | 英文 204 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

骨癌治療市場規模預計在 2025 年達到 14.233 億美元，預計到 2032 年將達到 20.296 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 5.2%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	14.233億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年複合年成長率：	5.20%	2032年的價值預測	20.296億美元

癌症是一種致命的慢性疾病，由於其高度侵襲性和長期疾病史而具有高死亡率。骨癌是一種在骨組織中不受控制地生長的癌症。骨癌市場按骨癌類型細分為：原發性骨癌和續發性骨癌。原發性骨癌是由於骨骼和相關組織快速且不受控制地生長而導致的癌症。另一方面，次發性骨癌是一種起源於身體其他部位並轉移到骨骼的癌症。骨癌也分為骨癌、伊文氏肉瘤、軟骨肉瘤、脊索瘤、纖維肉瘤和腺瘤。

市場動態

預計預測期內，越來越多的新藥上市和監管部門核准的骨癌市場將會成長。例如，2020 年 5 月，百時美施貴寶和藍鳥生物宣布，美國食品藥物管理局(FDA) 拒絕了 2020 年 3 月提交的 idecabutadien bicleucel (idecel; bb2121) 用於治療多次治療後的復發和難治性多發性骨髓瘤的生技藥品核准(BLA)。此外，2016 年 4 月，Advaxis, Inc. 的 Lm Technology 免疫療法產品 ADXS-HER2接受了美國FDA 的快速通道認證，該產品針對 HER2 表達癌症，用於治療可手術切除的骨癌。 FDA的快速通道認證將使該公司能夠進一步加快其開發進程，為患者提供更快、更好的治療。

本次調查的主要特點

本報告對全球骨癌藥物市場進行了詳細分析，並提供了預測期 2025-2032 的市場規模（百萬美元）和年複合成長率（CAGR%），以 2024 年為基準年。
它還強調了各個領域的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球骨癌治療市場的主要企業。
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、最新策略、市場擴張和行銷策略做出明智的決策。
全球骨癌治療藥物市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球骨癌治療市場的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 1,423.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.20%	2032 Value Projection:	USD 2,029.6 Mn

Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing's sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA's Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.

Key features of the study

This report provides in-depth analysis of the global bone cancer drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global bone cancer drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market.

Market Segmentation

By Drug Type Insights (Revenue, USD Mn, 2020 - 2032)
- Antimetabolites
- Anthracyclines
- Antibiotics
- Others (RANK ligand inhibitors, etc.)
By Disease Indication Insights (Revenue, USD Mn, 2020 - 2032)
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing's Sarcoma
By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co.
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Market Trends
Regulatory Scenario
New Product Launches/Approvals
Merger, Acquisition and Collaboration Scenario
PEST Analysis
PORTER's Analysis

4. Global Bone Cancer Drugs Market, By Drug Type, 2020- 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Others (RANK ligand inhibitors, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)

5. Global Bone Cancer Drugs Market, By Disease Indication, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)
Osteosarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)
Chondrosarcoma
- Introduction
Ewing's Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)

6. Global Bone Cancer Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)

7. Global Bone Cancer Drugs Market, By Region, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Advaxis, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Cellectar Biosciences, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- OPKO Health, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Amgen Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Debiopharm Group
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Merck & Co.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bayer AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bristol-Myers Squibb Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Hoffmann-La Roche Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Analyst Views